403
Participants
Start Date
May 31, 2008
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
Cimzia
"* Active substance: Certolizumab Pegol~* Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous use"
284, Lakewood
285, Littleton
278, New Port Richey
300, Winter Park
276, Chicago
279, Louisville
275, Metairie
307, Monroe
281, Annapolis
295, Towson
310, Chesterfield
298, Rochester
272, Raleigh
296, Cincinnati
289, Cleveland
280, Lancaster
305, Germantown
306, Germantown
308, Norfolk
290, Seattle
15, Concord
20, Box Hill
12, Footscray
16, Parkville
14, Bankstown
11, Fitzroy
13, Fremantle
18, Garran
270, Vienna
32, Bonheiden
31, Ghent
35, Leuven
34, Liège
30, Roeselare
52, Porto Alegre
45, Belo Horizonte
41, Curitiba
51, Rio de Janeiro
53, Santos
55, São Paulo
64, Edmonton
60, Winnepeg
67, Hamilton
62, Kingston
63, London
70, London
66, Toronto
68, Toronto
95, Hradec Králové
97, Hradek Kralove
98, Prague
100, Tallinn
101, Tartu
140, Homburg
137, Kiel
144, Ulm
130, Wilhelmshaven
151, Budapest
155, Budapest
156, Budapest
154, Győr
150, Nagykanizsa
153, Szeged
152, Szombathely
161, Beersheba
164, Haifa
167, Holon
163, Kfar Saba
166, Petha Tikva
160, Tel Aviv
169, Ẕerifin
176, Padua
171, Roma
174, Roma
191, Riga
192, Riga
193, Riga
202, Milford
204, Newton
201, Auckland
200, Christchurch
203, Hamilton
217, Częstochowa
218, Częstochowa
210, Lodz
211, Warsaw
212, Warsaw
213, Wroclaw
221, Cluj-Napoca
225, Constanța
232, Kazan'
230, Moscow
234, Moscow
233, Saint Petersburg
258, Dniepropetrovsk
251, Donetsk
256, Kiev
259, Kiev
257, Lviv
254, Simferopol
Collaborators (1)
PPD Development, LP
INDUSTRY
UCB BIOSCIENCES GmbH
INDUSTRY